-
Product Insights
NewNet Present Value Model: Taysha Gene Therapies Inc’s TSHA-102
Empower your strategies with our Net Present Value Model: Taysha Gene Therapies Inc's TSHA-102 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Bicycle Therapeutics Plc’s BT-8009
Empower your strategies with our Net Present Value Model: Bicycle Therapeutics Plc's BT-8009 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewMyoclonic Seizure – Drugs In Development, 2024
Empower your strategies with our Myoclonic Seizure – Drugs In Development, 2024 report and make more profitable business decisions. Myoclonic seizures cause a quick, uncontrollable muscle movement with no change in level of awareness or consciousness. They are characterized by brief, jerking spasms of a muscle or a group of related muscles, but can sometimes affect wider areas of body. The Myoclonic Seizure drugs in development market research report provide comprehensive information on the therapeutics under development for Myoclonic Seizure, complete...
-
Product Insights
NewAngelman Syndrome – Drugs In Development, 2024
Empower your strategies with our Angelman Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Angelman syndrome, an intricate genetic disorder primarily impacting the nervous system, manifests with distinctive features such as delayed development, intellectual disability, severe speech impairment, and ataxia, involving movement and balance issues. Recurrent seizures (epilepsy) and microcephaly, characterized by a small head size, are also prevalent in affected children. Recognizable at 6 to 12 months of age, delayed development intensifies in early childhood....
-
Product Insights
NewTay-Sachs Disease – Drugs In Development, 2024
Empower your strategies with our Tay-Sachs Disease – Drugs In Development, 2024 report and make more profitable business decisions. Tay-Sachs disease is a rare, inherited metabolic disease that mostly affects young children and involves progressive damage to and death of cells, particularly in the brain. It is caused by a mutation in the enzyme hexosaminidase A, which allows the harmful buildup of lipids (fatty materials such as oils and acids) in cells. Both parents must carry the mutated gene in order...
-
Product Insights
NewGeneralized Seizures – Drugs In Development, 2024
Empower your strategies with our Generalized Seizures – Drugs In Development, 2024 report and make more profitable business decisions. Generalized seizures, are a type of seizure that impairs consciousness and distorts the electrical activity of the whole or a larger portion of the brain. It occurs when the abnormal electrical activity causing a seizure begins in both halves (hemispheres) of the brain at the same time. Generalized seizures occur in various seizure syndromes, including myoclonic epilepsy, familial neonatal convulsions, childhood absence...
-
Product Insights
NewLafora Disease (Unverricht Disease) – Drugs In Development, 2024
Empower your strategies with our Lafora Disease (Unverricht Disease) – Drugs In Development, 2024 report and make more profitable business decisions. Unverricht-Lundborg disease (EPM1) a rare and fatal genetic neurodegenerative disorder that causes progressive myoclonic epilepsy. It is caused by mutations of the cystatin B gene. It typically presents in adolescents with new onset seizures along with symptoms such as lack of motor coordination, impaired mental function, and depression. It is diagnosed with a skin biopsy that shows Lafora bodies in...